The Myelodysplastic Syndromes (MDS) Foundation
The Myelodysplastic Syndromes (MDS) Foundation was created by a group of international physicians and researchers who wanted to make sure that information about MDS was always available. Now, the organization has developed to include patient advocacy groups, research funding, and educational initiatives. In addition, the MDS Foundation works to set up an international information network to contact patients for available clinical trials, thus sharing new treatment options in the community.
Condition Awareness & Advocacy
Here is a list of conditions this partner raises awareness and advocacy for:
Resources & Support
Patient Worthy Posts on Myelodysplastic syndromes
Free MDS Patient & Family/Caregiver Forum in Dallas!
One of our partner organizations, the MDS Foundation, is hosting another free MDS Patient & Family Forum in Dallas, Texas. When: Saturday, November 9th, 2019 Where: Aloft
Upcoming Free MDS event in Missouri!
One of our partner organizations, the MDS Foundation, is hosting another free MDS Patient & Family Forum in conjunction with Kansas University Medical Center, with
Experimental Treatment for Pancreatic Cancer has Earned Orphan Drug Designation
According to a story from BioSpace, the biopharmaceutical company CrystalGenomics, Inc. recently announced that the US Food and Drug Administration (FDA) has granted the company’s
Free MDS Forum in TN!
Our partner organization, The MDS Foundation, Inc., is sponsoring another free myelodysplastic syndromes (MDS) Patient & Family/Caregiver Forum in Nashville, Tennessee. When: Thurs., September 19,
FDA Approves an Experimental Treatment of Various Blood Malignancies for Clinical Trials
According to a story from First World Pharma, the biopharmaceutical company Mustang Bio, Inc. recently announced that the US Food and Drug Administration (FDA) has
-300x300.jpg)
The Controversy Surrounding Stem Cell Transplants
Genomic studies and advances in technology have increased researchers’ knowledge of several genetic syndromes that put people at risk for acute myeloid leukemia (AML).
